Indivior Announces Key Change to Stock Listings
Indivior PLC (Nasdaq: INDV) has marked a significant turn in its operational strategy by announcing the cancellation of its secondary listing on the London Stock Exchange (LSE). This decision aims to enhance the company’s business structure by maintaining its primary listing on Nasdaq.
Reasons Behind the London Delisting
The company’s Board reflected on the benefits associated with consolidating its listing on Nasdaq, primarily driven by the need to focus on its most lucrative business opportunities, particularly the U.S. market. The decision comes in light of the increasing liquidity and trading volumes observed on Nasdaq, where over 80% of Indivior's net revenue is generated.
Alignment with Business Goals
The Board is convinced that the delisting will better align with Indivior’s strategic focus. This move eliminates the burden of maintaining an additional listing and allows the firm to direct resources toward expansion and improving shareholder value. The choice reflects an understanding of where the majority of the company’s shareholder base resides, with a substantial 70% being based in the U.S.
What It Means for Shareholders
While the London listing will effectively cease, shareholders can still trade their shares on Nasdaq, which is expected to streamline their access to trading. Indivior is providing shareholders approximately 40 business days' notice of this significant transition.
No Expected Disruption for Shareholders
This shift is anticipated to have no adverse effects for shareholders who currently hold Ordinary Shares either directly or via a custody service. As per the company’s communication, current arrangements for U.K. Depository Interests (U.K. DIs) and Corporate Sponsored Nominee (CSN) participants remain intact, allowing continued participation without immediate changes.
Company’s Vision and Future Outlook
Indivior’s focus is on delivering transformative solutions for opioid use disorder (OUD). With their headquarters in the United States and a team of over 1,000 professionals worldwide, the organization is determined to ensure all patients have access to effective treatment options.
Commitment to Innovation
The company’s dedication extends to developing innovative products aimed at combating global health crises. Indivior's ongoing commitment signifies that even as they simplify their stock listings, their mission to assist patients remains unwavering.
Frequently Asked Questions
Why is Indivior cancelling its London listing?
The decision to cancel the London listing is based on the company's aim to concentrate on its primary listing in the U.S., which is where the majority of its business and shareholders are located.
What are the benefits of this move?
The change simplifies the company's listing structure, reduces costs associated with maintaining a secondary listing, and aligns its operations more closely with its U.S. market strategy.
How will shareholders be affected?
Shareholders are encouraged that they will continue to hold their shares and trade on Nasdaq without complications. No immediate action is required on their part.
What is Indivior's focus moving forward?
Indivior is focused on developing treatments for opioid use disorder and expanding its product lineup to better meet patient needs globally.
How can shareholders stay informed about future changes?
Indivior will provide timely updates and details concerning any further changes that may impact shareholders, ensuring they have the necessary information for making informed decisions.
